Seres therapeutics reports fourth quarter and full year 2023 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates. “2023 was an historic year for seres as we launched our first-in-class oral microbiome therapeutic, vowst, for recurrent cdi into commercialization with our collaborators at nestlÉ health science,” said eric shaff, president and chief executive officer of seres. “we are proud of th.
MCRB Ratings Summary
MCRB Quant Ranking